查尔斯河 2024年度报告

Annual Report2024| Charles River Laboratories Because every moment matters Our vision is to pioneer new and innovativesolutions that help our clients tackle one ofthe toughest barriers to the success of theirnew therapies—drug development timelines. We stand at a defining moment in our industry—where digital innovation,an unwavering commitment to patient safety, and the pursuit of alternativetechnologies are converging to reshape the future of drug development.Scientific and technological breakthroughs are not just accelerating discovery;they are redefining what’s possible. At Charles River, we embrace this transformation as a catalyst for progress.With an unmatched portfolio built on world-class science, we don’t justsupport drug development—we elevate it. Every study is approached with thesame care and dedication as if it were our own, ensuring integrity, scientificexcellence, and innovation at every step. Bringing a new therapy from discovery to patients is a journey filled withcomplexity, but also with extraordinary potential. We are committed tobreaking barriers, streamlining timelines, and driving the next wave ofinnovation, so that the life-changing treatments of tomorrow reach patientsfaster and more efficiently. We don’t just envision the future of drug development. We’re shaping it.Because when it comes to improving lives, every moment matters. As we look back on 2024, we do sowith gratitude for the dedication of ouremployees, the trust of our clients, and thecontinued support of our shareholders. James C. FosterChair, President & Chief Executive Officer Despite the challenging market environment, or in fact becauseof it, many of our global biopharmaceutical and biotechnologyclients chose to benefit from the long-term value of strategicoutsourcing. Our clients continued to rely on their relationshipswith Charles River to enhance their drug discovery and early-stage development efforts and to assist them in bringingnew drugs to market by improving their operating efficiency,speed to market, and access to capabilities that they do notmaintain internally. However, because of their more cautiousview with regard to early-stage R&D spending, revenue fromboth global biopharmaceutical clients and small and mid-sizedbiotechnology clients declined in fiscal year 2024. To Our Shareholders This year, we enhanced our role as a trusted partner for ourclients’ drug discovery and non-clinical development programs.Our ability to deliver our leading suite of services and productshas led clients to continue to choose to partner with CharlesRiver for our flexible and efficient outsourcing solutions,broad scientific capabilities, and global scale. Our unwaveringcommitment to accelerating the pace of biomedical researchhas allowed us to support our clients’ quests to bring therapiesto patients more efficiently, while taking significant action todrive our own internal efficiency. 2024 was another year of progress at Charles River when wedemonstrated the resilience of our organization during a timethat was not without its challenges. Globally, biopharmaceuticalclients intensified their actions around restructuring initiativesaimed at improving efficiency. They reprioritized drugdevelopment programs and focused on late-stage clinicalpipelines. These actions led to constrained spending ondiscovery and early-stage development. Importantly, our long-term vision remains unchanged:to help our clients bring life-changing therapies to marketas quickly and safely as possible. Whether supportingglobal biopharmaceutical companies, small and mid-sizedbiotechnology firms, or academic institutions, we take pride inthe critical role we play in the development of new treatmentsfor patients in need. Our ability to provide an integrated suiteof solutions—from early discovery through safety assessmentand manufacturing—has never been more valuable, as theindustry increasingly seeks end-to-end partners to streamlinedrug development. We are confident that the long-term,underlying fundamentals for our Company remain intact andthat biopharmaceutical demand for preclinical services willeventually return. The impetus for these actions was a combination of factorsincluding the macroeconomic slowdown, pending drug patentexpirations, and the impact of the Inflation Reduction Act(IRA) on drug pricing. In addition, while small and mid-sizedbiotechnology companies benefited from a more favorablefunding environment in fiscal year 2024, recovery for this clientbase has occurred at a more gradual pace than anticipated,due in part to uncertainty around future funding levels and thebroader interest rate environment. As we look back on 2024, we do so with gratitude for thededication of our employees, the trust of our clients, and Financial Results ($ in millions, except per share data) the continued support of our shareholders. It is through ourcollective efforts that Charles River has been able to navigatechallenges, capitalize on opportun